Catalyst Crew Technologies Corp. (OTC: CCTC) has announced the development of PulmoAI, an artificial intelligence-enabled module designed to support the detection and predictive analysis of pulmonary diseases. The platform is intended to assist healthcare providers in analyzing respiratory health data and identifying potential clinical risks through AI-driven analytics.
PulmoAI's proposed capabilities include automated interpretation of thoracic imaging, detection of pulmonary abnormalities, and predictive modeling of disease progression. The platform is being developed to integrate multiple data inputs, including computed tomography (CT) scans, chest X-rays, pulmonary function tests, and inflammatory biomarkers, in order to generate structured outputs intended to support clinical review and care coordination.
According to the company, PulmoAI forms part of its broader artificial intelligence healthcare platform and is expected to function as a specialized module within Catalyst Crew's digital health ecosystem. Management believes that modular AI systems, such as PulmoAI, may support scalable deployment across telehealth services, remote diagnostics, and technology-enabled healthcare delivery environments.
The company intends to integrate PulmoAI across its existing and planned healthcare infrastructure initiatives, including its healthcare services coordination platform. As development progresses, PulmoAI is expected to support early detection capabilities and data-driven insights across multiple points of care.
Catalyst Crew Technologies intends to prioritize market development in Latin America, where the company believes AI-enabled healthcare technologies may help expand access to respiratory diagnostics, support earlier identification of pulmonary conditions, and improve healthcare system efficiency. Dr. Kevin Rodan Levy, Chief Executive Officer, stated: "Artificial intelligence has the potential to enhance how healthcare providers detect and monitor pulmonary conditions, particularly in environments where access to specialized diagnostics may be limited. PulmoAI reflects our commitment to building scalable, technology-driven solutions to support healthcare delivery."
The company intends to continue developing and refining PulmoAI and its broader healthcare technology platform while evaluating opportunities for pilot programs, strategic partnerships, and phased market deployment. For more information, visit https://catalystcrewai.com or review the company's filings with the U.S. Securities and Exchange Commission at www.sec.gov.
